# Capmatinib

Source: https://onco.cc/drugs/capmatinib/  
OnCo record `capmatinib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Capmatinib is a targeted pill for the small group of lung cancers driven by a MET exon 14 skipping mutation, found by tumour sequencing.

## Summary

Capmatinib is an oral MET inhibitor for metastatic non-small cell lung cancer whose tumours carry a MET exon 14 skipping mutation, present in roughly 3 to 4 percent of lung adenocarcinomas. In the GEOMETRY mono-1 trial it produced responses in most untreated patients and in a smaller share of previously treated ones. The FDA granted accelerated approval in 2020. NICE did not complete its appraisal, so it is not routinely funded in England. Peripheral oedema and nausea are the common side effects.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-08
- Also known as: INC280
- Tags: gap-fill
- Brand: Tabrecta
- Modality: Small-molecule MET tyrosine kinase inhibitor
- Mechanism: A selective, ATP-competitive inhibitor of the MET receptor kinase; tumours with MET exon 14 skipping mutations keep the receptor switched on, and blocking it shuts down the growth signal.
- Approvals: US 2020: Metastatic NSCLC with a MET exon 14 skipping mutation (accelerated approval)

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Capmatinib
- GEOMETRY mono-1 (NEJM 2020): https://doi.org/10.1056/NEJMoa2002787
- Label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=capmatinib

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [MET](https://onco.cc/targets/met/)
- drugs: [Crizotinib](https://onco.cc/drugs/crizotinib/), [Tepotinib](https://onco.cc/drugs/tepotinib/)
- companies: [Novartis](https://onco.cc/companies/novartis/)

---
JSON: https://onco.cc/api/v1/entities/capmatinib.json